# A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

> **NCT04612699** · PHASE2 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 123 (actual)

## Conditions studied

- Moderate-to-Severe Plaque Psoriasis

## Interventions

- **DRUG:** Jaktinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04612699
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-11
- **Primary completion:** 2022-08-15
- **Final completion:** 2022-08-15
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04612699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04612699, "A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04612699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*